Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 17, 2024

Primary Completion Date

August 6, 2024

Study Completion Date

December 31, 2024

Conditions

Paroxysmal Nocturnal Hemoglobinuria，IgA Nephropathy

Interventions

DRUG

HRS-5965 tablets；HRS-5965 capsules

Medication regimen: 1 Drug: HRS-5965 tablets Medication regimen: 2 Drug: HRS-5965 capsules

Trial Locations (1)

ZhongShan Hospital FuDan University, Shanghai

All Listed Sponsors

lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY

NCT06490991 - Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter